These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7875020)

  • 1. Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole.
    Kunová A; Trupl J; Spánik S; Drgona L; Sufliarsky J; Lacka J; Studená V; Hlavácová E; Studená M; Kukucková E
    Chemotherapy; 1995; 41(1):39-44. PubMed ID: 7875020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis.
    Kunova A; Trupl J; Demitrovicova A; Jesenska Z; Grausova S; Grey E; Pichna P; Kralovicova K; Sorkovska D; Krupova I; Spanik S; Studena M; Koren P; Krcmery V
    Microb Drug Resist; 1997; 3(3):283-7. PubMed ID: 9271000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
    Kucukates E; Erturan Z; Susever S; Yegenoglu Y
    APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
    Krcmery V; Barnes AJ
    J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
    Wingard JR; Merz WG; Rinaldi MG; Johnson TR; Karp JE; Saral R
    N Engl J Med; 1991 Oct; 325(18):1274-7. PubMed ID: 1669837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010].
    Porte L; León P; Gárate C; Guzmán AM; Labarca J; García P
    Rev Chilena Infectol; 2012 Apr; 29(2):149-55. PubMed ID: 22689028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
    Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
    Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeasts species distribution in Neonatal Intensive Care Units in northeast Argentina.
    Giusiano GE; Mangiaterra M; Rojas F; Gómez V
    Mycoses; 2004 Aug; 47(7):300-3. PubMed ID: 15310334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
    Yang YL; Li SY; Cheng HH; Lo HJ;
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.
    Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002.
    Wang JL; Chang SC; Hsueh PR; Chen YC
    J Microbiol Immunol Infect; 2004 Aug; 37(4):236-41. PubMed ID: 15340652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
    Durán MT; Velasco D; Canle D; Moure R; Villanueva R
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.